CD274 and non-small cell lung carcinoma: Furthermore, the authority has recently approved pembrolizumab in conjunction with platinum-dependent chemotherapies in unresectable enhanced NSCLC regardless of PD-L1 level, making it the benchmark of therapy in this context.